|Bid||1.8700 x 2200|
|Ask||1.8800 x 900|
|Day's Range||1.8600 - 2.0500|
|52 Week Range||1.0000 - 9.7100|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.36|
Sientra (SIEN) delivered earnings and revenue surprises of 7.14% and 0.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Achieves Record Fourth Quarter Net Sales and Strong Growth Across Both Business Segments Well-Capitalized Balance Sheet Provides Enhanced Flexibility to Execute on Strategic.
Sientra intends to use the proceeds from this financing for continued investment in its commercial activities, strategic growth opportunities and general corporate purposes. The notes are convertible at a conversion price representing a 35% premium over Sientra’s closing stock price of $3.04 on March 10, 2020, resulting in a conversion price of $4.10 per share.
NEW YORK, NY / ACCESSWIRE / March 11, 2020 / Sientra, Inc. (NASDAQ:SIEN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2020 at 5:00 PM Eastern ...
Sientra, Inc. (SIEN), a medical aesthetics company, announced today that it will release 4Q19 financial results after the close of trading on Wednesday, March 11, 2020. Sientra will host a conference call to discuss financial results the same day at 5:00 p.m. Eastern Time. The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers.
SANTA BARBARA, Calif., Feb. 20, 2020 -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced today that members of management are scheduled to present at the.
The new employees were granted restricted stock units representing a total of 100,862 shares of common stock. The restricted stock units will vest in time-based installments beginning on the grant date. In each case, the vesting of shares is contingent upon the recipient’s continued service with the Company through each vesting date.
When shares fall, investor focus locks in. The first instinct, for some, is to avoid the name entirely after the investing alarm bells have been sounded. Sure, dropping share prices can indicate that there’s a deeper issue hampering the company such as weak fundamentals or headwinds that appear unbeatable. Having said that, this isn’t the case for every stock that has seen its share price take a hit.Wall Street pros remind investors that while not all beaten-down names are primed for a recovery, others offer investors a unique buying opportunity, with their current share prices reflecting an attractive entry point.So, how are investors supposed to know when it’s time to buy the dip? TipRanks' Stock Screener tool helped us zero in on 3 compelling stocks, specifically in the healthcare industry, by filtering our search results by sector, analyst consensus and price target upside. While these names have taken a beating, each has generated substantial bullish sentiment from the analysts and boasts massive upside potential from current levels. Let’s dive right in.Sientra, Inc. (SIEN)First up, we have Sientra, a company that is best known for producing implants and other products for breast augmentation or reconstruction procedures. While the healthcare name has started off 2020 down 25%, Wall Street analysts see better days on the horizon.The recent weakness actually follows a relatively solid preliminary fourth quarter revenue announcement. On January 13, the company told investors that miraDry’s better-than-expected performance drove a modest revenue beat. However, the breast segment missed the mark and there are still some concerns regarding its balance sheet as its cost restructuring efforts won't generate cash flow benefits until 2021.That being said, Leerink Partners analyst Richard Newitter points out that the breast segment still achieved 20%-plus growth, and his conversation with SIEN management actually implies that its breast implant business accelerated. Additionally, he stated that if one-time events are excluded, cash burn improved.As a result, he argues that the pullback is “too excessive.“ “We've seen SIEN's stock react unexplainably negative in the past to otherwise solid results (i.e., initially after a 2Q19 beat) only to recover shortly thereafter. We think this will prove to be one of those situations and reiterate our OP rating as we continue to believe SIEN's valuation discount is disconnected from an over 20% top-line growth profile,” he explained.With Newitter anticipating that its OPUS implant launch and miraDry sales growth will also help fuel a recovery, it makes sense that he still sides with the bulls. To this end, the five-star analyst reiterated an Outperform recommendation and $13 price target. Should this target be met, shares could be in for a 93% twelve-month gain. (To watch Newitter’s track record, click here)What does the rest of the Street think? Based on 100% Street support, or a total of 6 bullish calls assigned in the last three months, the consensus rating is a unanimous Strong Buy. The $13.20 average price target puts the upside potential above Newitter’s forecast at 96%. (See Hercules Capital’s stock analysis at TipRanks)ViewRay, Inc. (VRAY)ViewRay is focused on giving clinicians new and more effective ways to treat cancer using radiation. Its approach uses MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. With this groundbreaking offering, why have shares dipped 25% year-to-date?The share price decline comes on the heels of its preliminary Q4 results. VRAY announced that it expects quarterly sales of $17 million, landing very close to the consensus estimate. However, new orders largely disappointed, with this figure coming in at $21 million. As this is down from $49 million in the prior-year quarter, it’s no wonder investors have been concerned. It also didn’t help that VRAY burned through about $3 million in cash.That isn’t to say investors should give up on the healthcare name. Piper Sandler’s Matthew O'Brien did acknowledge the result was unexpected “as momentum in the order book appeared to have been building with eight orders (three upgrades) last quarter.” However, he argues that the soft order figure is indicative of “standard lumpiness capital equipment sales”, which should improve in the coming quarters.“Although we do not expect this to be the last bump in the road, we remain highly confident in the utility of the MRIdian as the best technology to treat cancer patients, and we believe it will yield significant share-taking over the next couple of years,” O’Brien commented. He added, “We believe today’s dip represents a buying opportunity to investors willing to weather some quarterly volatility...”As recent investments from heavyweights Medtronic and Elekta boosted its capital, VRAY should be able to improve system install times as well as access potential hospital targets for the MRIdian system. Based on all of these factors, the five-star analyst maintained an Overweight rating and $6 price target. At this target, shares could soar 89% in the next twelve months. (To watch O’Brien’s track record, click here)Like O’Brien, other Wall Street analysts are staying on board. 6 Buys and a single Hold issued in the last three months add up to a Strong Buy analyst consensus. In addition, the $6.71 average price target implies 112% upside potential. (See ViewRay stock analysis on TipRanks)Evolus, Inc. (EOLS) Evolus is giving people a reason to smile, offering an FDA-approved injectable medicine to improve the appearance of frown lines. Despite shedding 19% of its value since the beginning of 2020, one analyst believes that EOLS will be able to turn investors’ frowns upside down.Marc Goodman of Leerink Partners wrote in a recent note that he suggests “aggressive buying of EOLS shares” after the stock’s tumble. Shares set off on a downward trajectory after it pre-announced its fourth quarter results. Total sales could land within the range of $18.5 million to $19.5 million, compared to the $16.1 million consensus estimate. In addition, the amount of purchasing accounts is expected to increase substantially from about 2,000 in the third quarter to almost 3,500 in the fourth quarter.“We are baffled by the weakness today and view as a great buying opportunity. In our view, commercial execution by this management team has been excellent so far and the sales ramp is very encouraging. From a ‘back of the envelope’ view we simplistically say that if this is just a $250 million peak sales product, these types of aesthetics assets trade for at least 5x sales, and thus that implies a valuation at least 3x where the stock currently trades,” Goodman noted.Even though the four-star analyst points out that investors have been worried about the lockup period for Alphaeon, which owns 26%, and the ITC litigation, he doesn’t think that either hampers its long-term growth prospects.Bearing this in mind, he kept his Outperform rating and $25 price target as is. This target conveys his confidence in Evolus’ ability to climb 154% higher in the twelve months ahead. (To watch Goodman’s track record, click here)Looking at the consensus breakdown, 6 Buys, 1 Hold and 1 Sell make the consensus rating a Moderate Buy. It should be noted, though, that the average price target of $26.88 indicates a whopping 173% potential twelve-month gain. (See Evolus stock analysis on TipRanks)
Sientra, Inc. (NASDAQ:SIEN) shareholders should be happy to see the share price up 18% in the last quarter. But don't...
Sientra, Inc. (SIEN), a medical aesthetics company, today announced preliminary unaudited net sales for the fourth quarter 2019. In addition, the Board of Directors has appointed global commercial leader Caroline Van Hove as a director of Sientra effective January 10, 2020.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
The WeTrader Paper Trading Competition , a 5-week paper trading contest hosted by the zero-commission trading platform Webull, has officially ended. Here’s a look at how the 83 contestants—the top 10 portfolios ...
Sientra (SIEN) delivered earnings and revenue surprises of 8.16% and 11.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Highlights: Record total net sales of $22.4 million in 3Q19, growth of 33% year over yearBreast Products net sales of $12.6 million in 3Q19, growth of 47% year over.
Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra” or the “Company”), announced today the acquisition of the dedicated FDA-approved silicone breast implant manufacturing operation in Franklin, Wisconsin, from Lubrizol Life Science. Lubrizol Life Science will turn over to Sientra a turnkey, fully operational Class 3 breast implant manufacturing operation that is now 19 months into commercial scale-up with established capacity that continues a steady ramp to position the Company to meet its near-term and long-term commercial objectives.
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
SANTA BARBARA, Calif., Oct. 31, 2019 -- Sientra, Inc. (Nasdaq: SIEN), a medical aesthetics company, announced today that its management team will participate in the following.
Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sientra, Inc. (SIEN), a medical aesthetics company, announced today that it will release financial results for the third quarter 2019 after the close of trading on Thursday, November 7, 2019. Sientra will host a conference call to discuss financial results the same day at 5:00 p.m. Eastern Time. The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers.